Peter Yau, MD
Pulmonary Disease · Temple, TXNPI 1790954758
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $56,945 of the $61,348 with a category attached, or 92.8%. Actelion Pharmaceuticals US, Inc. accounts for 96.9% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $22,887, more than ten times the $185 reported in 2019. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 82 payments — averaging $748.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$59K
- Bayer$2K
- Inari Medical, Inc.$116
- Merck$101
- Inspire Medical Systems, Inc.$65
- GE HealthCare$19
- plus $3 from 1 others
Across 20 payments — averaging $1791.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$31K
- United Therapeutics Corporation$5K
What the payments were for
- Consulting fees$1,5423%
- Speaking & faculty fees$56,94593%
- Travel & lodging$1950%
- Food & beverage$2,6634%
- Education$30%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 75 | $59,425 |
| Bayer | 2 | $1,618 |
| Inari Medical, Inc. | 1 | $116 |
| Merck | 1 | $101 |
| Inspire Medical Systems, Inc. | 1 | $65 |
| GE HealthCare | 1 | $19 |
| United Therapeutics Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$57,882
- OPSUMIT$57,639
- Adempas$1,542
- FLOWTRIEVER CATHETER, S$116
- CT THROMBECTOMY SYSTEM KIT$116
- WINREVAIR$101
How this compares
$61,348 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 289 | $3,636,729 |
| UptraviSelexipag | 104 | $2,638,392 |
| Tyvaso DpiTreprostinil | 34 | $802,274 |
| AdempasRiociguat | 44 | $609,715 |
| WinrevairSotatercept-Csrk | 36 | $512,290 |
| LetairisAmbrisentan | 22 | $288,439 |
| TracleerBosentan | 11 | $137,719 |
| Ambrisentan | 30 | $112,824 |
| AdcircaTadalafil | 15 | $96,548 |
| Orenitram ErTreprostinil Diolamine | 11 | $74,684 |
| Dupixent PenDupilumab | 15 | $58,703 |
| Tadalafil | 69 | $44,180 |
| Sildenafil Citrate | 162 | $27,356 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $20,247 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $19,964 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Tracleer | $59,425 | $6,412,839404 claims |
| BayerAdempas | $1,618 | $609,71544 claims |
| MerckWinrevair | $101 | $512,29036 claims |
| United Therapeutics CorporationAdcirca | $3 | $96,54815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Temple
- Brian FurukawaTemple$148K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.